KR101184374B1 - 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성 방법 - Google Patents

데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성 방법 Download PDF

Info

Publication number
KR101184374B1
KR101184374B1 KR1020117006692A KR20117006692A KR101184374B1 KR 101184374 B1 KR101184374 B1 KR 101184374B1 KR 1020117006692 A KR1020117006692 A KR 1020117006692A KR 20117006692 A KR20117006692 A KR 20117006692A KR 101184374 B1 KR101184374 B1 KR 101184374B1
Authority
KR
South Korea
Prior art keywords
tumor
kpu
dehydrophenylahistin
sub
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020117006692A
Other languages
English (en)
Korean (ko)
Other versions
KR20110039500A (ko
Inventor
요시오 하야시
제니퍼 그로드버그
마이클 팔라디노
Original Assignee
니리어스 파마슈티컬즈, 인코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니리어스 파마슈티컬즈, 인코퍼레이션 filed Critical 니리어스 파마슈티컬즈, 인코퍼레이션
Publication of KR20110039500A publication Critical patent/KR20110039500A/ko
Application granted granted Critical
Publication of KR101184374B1 publication Critical patent/KR101184374B1/ko
Assigned to 다롄 완춘 바이오테크놀로지 씨오., 엘티디. reassignment 다롄 완춘 바이오테크놀로지 씨오., 엘티디. 권리의 전부이전등록 Assignors: 니리어스 파마슈티컬즈, 인코퍼레이션
Assigned to 비욘드스프링 파마수티컬스, 인코포레이티드. reassignment 비욘드스프링 파마수티컬스, 인코포레이티드. 권리의 전부이전등록 Assignors: 다롄 완춘 바이오테크놀로지 씨오., 엘티디.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020117006692A 2002-08-02 2003-08-01 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성 방법 Expired - Lifetime KR101184374B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40107402P 2002-08-02 2002-08-02
US60/401,074 2002-08-02
US41112802P 2002-09-16 2002-09-16
US60/411,128 2002-09-16
US45006303P 2003-02-24 2003-02-24
US60/450,063 2003-02-24
PCT/US2003/024232 WO2004054498A2 (en) 2002-08-02 2003-08-01 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020057001947A Division KR101049100B1 (ko) 2002-08-02 2003-08-01 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성방법

Publications (2)

Publication Number Publication Date
KR20110039500A KR20110039500A (ko) 2011-04-18
KR101184374B1 true KR101184374B1 (ko) 2012-09-20

Family

ID=32600863

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117006692A Expired - Lifetime KR101184374B1 (ko) 2002-08-02 2003-08-01 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성 방법
KR1020057001947A Expired - Lifetime KR101049100B1 (ko) 2002-08-02 2003-08-01 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020057001947A Expired - Lifetime KR101049100B1 (ko) 2002-08-02 2003-08-01 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성방법

Country Status (19)

Country Link
US (4) US7064201B2 (cg-RX-API-DMAC7.html)
EP (1) EP1529044B1 (cg-RX-API-DMAC7.html)
JP (1) JP4616649B2 (cg-RX-API-DMAC7.html)
KR (2) KR101184374B1 (cg-RX-API-DMAC7.html)
CN (1) CN100540548C (cg-RX-API-DMAC7.html)
AT (1) ATE374767T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003302721B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0313363A8 (cg-RX-API-DMAC7.html)
CA (1) CA2494049C (cg-RX-API-DMAC7.html)
CO (1) CO5721010A2 (cg-RX-API-DMAC7.html)
DE (1) DE60316688T2 (cg-RX-API-DMAC7.html)
DK (1) DK1529044T5 (cg-RX-API-DMAC7.html)
ES (1) ES2295695T3 (cg-RX-API-DMAC7.html)
IL (2) IL166628A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA05001217A (cg-RX-API-DMAC7.html)
NZ (1) NZ538433A (cg-RX-API-DMAC7.html)
PT (1) PT1529044E (cg-RX-API-DMAC7.html)
WO (1) WO2004054498A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200501616B (cg-RX-API-DMAC7.html)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
EP1264831A4 (en) * 2000-01-18 2005-11-23 Nereus Pharmaceuticals Inc Cell division inhibitors and a method for fixing the same
JP5048201B2 (ja) 2000-08-04 2012-10-17 ディーエムアイ バイオサイエンシズ インコーポレイテッド ジケトピペラジン類の使用方法とジケトピペラジン類を含む組成物
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) * 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
AU2003302721B2 (en) 2002-08-02 2009-10-08 Beyondspring Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
DK1571970T3 (da) 2002-10-02 2011-11-28 Dmi Biosciences Inc Diagnose og monitorering af sygdomme
CN102210852B (zh) 2003-05-15 2016-10-19 安皮奥制药股份有限公司 T-细胞介导的疾病的治疗
BRPI0506655A (pt) * 2004-02-04 2007-05-08 Nereus Pharmaceuticals Inc dehidrofenilahistinas e seus análogos, e sìntese de dehidrofenilahistinas e seus análogos
ES2528363T3 (es) * 2004-12-06 2015-02-09 Pitney Pharmaceuticals Pty Limited Tratamiento para el cáncer
WO2006105051A2 (en) 2005-03-29 2006-10-05 Nereus Pharmaceuticals, Inc. Synthesis of diketopiperazines
JP2008024871A (ja) * 2006-07-24 2008-02-07 Fujifilm Corp インク組成物、インクジェット記録方法、印刷物、平版印刷版の製造方法、及び平版印刷版
KR100932093B1 (ko) 2006-09-27 2009-12-16 주식회사종근당 미세소관 형성 저해제로서 유용한 벤조페논 유도체
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ,インコーポレイテッド ジケトピペラジンを用いた医薬組成物
AU2009316773A1 (en) * 2008-11-21 2010-05-27 Isis Pharmaceuticals, Inc. Anticancer combination comprising docetaxel and an antisense oligonucleotide
JP5824511B2 (ja) 2010-05-03 2015-11-25 テイコク ファーマ ユーエスエー インコーポレーテッド 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp TREATMENT OF DISEASES
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JP2014530063A (ja) 2011-10-10 2014-11-17 アンピオ ファーマシューティカルズ,インコーポレイテッド 免疫寛容が高められた埋込み型医療用デバイス、ならびに製造方法および埋込み方法
PH12014500685B1 (en) 2011-10-10 2018-10-03 Ampio Pharmaceuticals Inc Treatment of degenerative joint disease
HK1198812A1 (en) 2011-10-28 2015-06-12 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
JP6311097B2 (ja) * 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
EP3076972B1 (en) 2013-10-11 2021-10-06 BeyondSpring, Inc. Cancer treatment with combination of plinabulin and taxane
EP4066836A1 (en) 2014-08-18 2022-10-05 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
MX394865B (es) * 2015-02-12 2025-03-24 Beyondspring Pharmaceuticals Inc Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
HK1249052A1 (zh) * 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
WO2016144636A1 (en) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
CN106279039B (zh) * 2015-06-02 2019-01-11 青岛海洋生物医药研究院股份有限公司 氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES
EP3334726B1 (en) * 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
CN109475524A (zh) 2016-06-06 2019-03-15 万春药业公司 用于减少中性粒细胞减少症的组合物和方法
CN107011322B (zh) * 2016-08-12 2020-02-18 青岛海洋生物医药研究院股份有限公司 一种脱氢苯基阿夕斯丁类化合物的制备纯化方法
EP4089085B1 (en) 2016-08-12 2024-04-03 Shenzhen Huahong Marine Biomedicine Co., Ltd Manufacturing and purification method of polycrystalline form of dehydrophenylahistin-like compound
CN107011331A (zh) * 2016-08-12 2017-08-04 青岛海洋生物医药研究院股份有限公司 脱氢苯基阿夕斯丁类化合物的多晶型及其制备方法
CN107778297B (zh) * 2016-08-12 2021-11-19 深圳华大海洋科技有限公司 氘代脱氢苯基阿夕斯丁类化合物的多晶型及其制备方法和应用
CN106565686B (zh) * 2016-10-11 2019-03-01 深圳海王医药科技研究院有限公司 微管蛋白抑制剂
CN106565685B (zh) * 2016-10-11 2019-03-01 深圳海王医药科技研究院有限公司 微管蛋白抑制剂
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
BR112019018880A2 (pt) 2017-03-13 2020-04-14 Beyondspring Pharmaceuticals, Inc. composições de plinabulina e seu uso
CN108658945B (zh) * 2017-03-31 2020-11-20 深圳海王医药科技研究院有限公司 一种微管蛋白抑制剂(vda-1)的a晶型
US11434225B2 (en) 2017-08-03 2022-09-06 Pliva Hrvatska D.O.O. Salts and solid state forms of plinabulin
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种治疗肿瘤的药物组合物及其应用
CN107698567B (zh) * 2017-10-25 2020-09-15 西南大学 靛红唑醇类化合物及其制备方法和医药应用
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
CN108299399A (zh) * 2018-02-01 2018-07-20 深圳海王医药科技研究院有限公司 一种小分子免疫化合物的晶型、其制备方法和含有其的药物组合物
US20210161888A1 (en) * 2018-06-01 2021-06-03 Beyondspring Pharmaceuticals, Inc. Composition and method of treating cancer associated with egfr mutation
CN109030642B (zh) * 2018-06-26 2021-03-09 深圳海王医药科技研究院有限公司 一种脱氢苯基阿夕斯丁类似物及其异构体的测定方法
CN111840291B (zh) * 2020-07-14 2021-12-21 深圳海王医药科技研究院有限公司 一种在肿瘤治疗中具有增效作用的化合物的应用
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
CN115703763A (zh) * 2021-08-13 2023-02-17 大连万春布林医药有限公司 普那布林或其制剂中的杂质及其用途
WO2023232113A1 (zh) * 2022-06-02 2023-12-07 上海旭成医药科技有限公司 哌嗪酮类化合物及其制备方法和用途
CN117285516B (zh) * 2022-06-16 2026-06-26 大连万众益生大健康有限公司 脱氢苯基阿夕斯汀类化合物、其制备方法及其应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
JP2026509292A (ja) 2023-03-10 2026-03-17 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド 腫瘍学的併用療法及びその使用方法
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2403790A1 (en) * 2000-01-18 2001-07-26 Nereus Pharmaceuticals, Inc. A cell division inhibitor and a production method thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
CA2149150C (en) * 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
JPH0725858A (ja) * 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
GB9402807D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402809D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) * 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) * 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) * 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5922683A (en) * 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
EP2201945B1 (en) * 1997-11-21 2013-03-06 Purdue Neuroscience Company Use of substituted 2-aminoacetamides for treating or ameliorating anxiety
EP1051397B1 (en) 1998-01-29 2008-12-31 Aventis Pharmaceuticals Inc. Method for preparing an n- (aliphatic or aromatic)carbonyl -2-aminoacetamide compound and a cyclyzed compound
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
IL137974A0 (en) * 1998-03-26 2001-10-31 Shionogi & Co Indole derivatives having antiviral activity
US6509331B1 (en) * 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) * 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6358957B1 (en) * 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US7026322B2 (en) * 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
WO2002064592A1 (en) * 2000-12-28 2002-08-22 Neurocrine Biosciences, Inc. Tricyclic crf receptor antagonists
US6569556B2 (en) * 2001-01-29 2003-05-27 General Motors Corporation Cooling system for a battery pack
US7919497B2 (en) * 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
AU2003302721B2 (en) * 2002-08-02 2009-10-08 Beyondspring Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
BRPI0506655A (pt) 2004-02-04 2007-05-08 Nereus Pharmaceuticals Inc dehidrofenilahistinas e seus análogos, e sìntese de dehidrofenilahistinas e seus análogos
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2403790A1 (en) * 2000-01-18 2001-07-26 Nereus Pharmaceuticals, Inc. A cell division inhibitor and a production method thereof

Also Published As

Publication number Publication date
JP2006511534A (ja) 2006-04-06
PT1529044E (pt) 2008-01-14
US20060223822A1 (en) 2006-10-05
IL166628A0 (en) 2006-01-15
AU2003302721A1 (en) 2004-07-09
JP4616649B2 (ja) 2011-01-19
WO2004054498A3 (en) 2004-11-25
WO2004054498A2 (en) 2004-07-01
DK1529044T3 (da) 2008-02-04
BR0313363A (pt) 2005-08-09
EP1529044A2 (en) 2005-05-11
AU2003302721B2 (en) 2009-10-08
US7674903B2 (en) 2010-03-09
CN1684955A (zh) 2005-10-19
US20060223823A1 (en) 2006-10-05
KR20050083610A (ko) 2005-08-26
ES2295695T3 (es) 2008-04-16
CO5721010A2 (es) 2007-01-31
ZA200501616B (en) 2005-11-30
DE60316688T2 (de) 2008-07-17
KR20110039500A (ko) 2011-04-18
US7064201B2 (en) 2006-06-20
BRPI0313363A8 (pt) 2019-01-02
ATE374767T1 (de) 2007-10-15
EP1529044B1 (en) 2007-10-03
NZ538433A (en) 2008-02-29
CA2494049A1 (en) 2004-07-01
HK1084388A1 (zh) 2006-07-28
CN100540548C (zh) 2009-09-16
HK1078080A1 (en) 2006-03-03
DK1529044T5 (da) 2008-04-21
MXPA05001217A (es) 2005-05-16
US20060217553A1 (en) 2006-09-28
US7956058B2 (en) 2011-06-07
DE60316688D1 (de) 2007-11-15
US20050090667A1 (en) 2005-04-28
CA2494049C (en) 2011-10-18
IL166628A (en) 2012-08-30
KR101049100B1 (ko) 2011-07-15

Similar Documents

Publication Publication Date Title
KR101049100B1 (ko) 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성방법
US7919497B2 (en) Analogs of dehydrophenylahistins and their therapeutic use
US8129527B2 (en) Analogs of dehydrophenylahistins and their therapeutic use
KR101228104B1 (ko) 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의합성방법
US7935704B2 (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
ZA200607151B (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
CN101633655B (zh) 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
US20040242896A1 (en) Azole compounds as anti-fungal agents
HK1078080B (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
HK1084388B (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
MXPA06008810A (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20110323

Application number text: 1020057001947

Filing date: 20050202

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110401

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110623

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120330

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110623

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20120430

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20120330

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20120618

Appeal identifier: 2012101004126

Request date: 20120430

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20120430

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20120430

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20110922

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20120618

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20120531

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

FPAY Annual fee payment
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20120913

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20120914

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20150819

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20150819

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20160818

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20160818

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20170818

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20170818

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20180816

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20180816

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20190816

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20190816

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20200819

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20200819

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20210818

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20210818

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20220728

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20220728

Start annual number: 11

End annual number: 11

PC1801 Expiration of term

Termination date: 20240201

Termination category: Expiration of duration